OPKO Health (NASDAQ:OPK – Get Free Report) and Tempus AI (NASDAQ:TEM – Get Free Report) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, dividends, analyst recommendations, risk, profitability and earnings.
Insider & Institutional Ownership
64.6% of OPKO Health shares are held by institutional investors. Comparatively, 24.2% of Tempus AI shares are held by institutional investors. 44.7% of OPKO Health shares are held by insiders. Comparatively, 24.3% of Tempus AI shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Analyst Recommendations
This is a summary of recent ratings and target prices for OPKO Health and Tempus AI, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| OPKO Health | 1 | 2 | 4 | 1 | 2.62 |
| Tempus AI | 2 | 9 | 11 | 0 | 2.41 |
OPKO Health presently has a consensus target price of $2.96, suggesting a potential upside of 93.63%. Tempus AI has a consensus target price of $72.37, suggesting a potential upside of 11.82%. Given OPKO Health’s stronger consensus rating and higher probable upside, equities research analysts clearly believe OPKO Health is more favorable than Tempus AI.
Earnings and Valuation
This table compares OPKO Health and Tempus AI”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| OPKO Health | $606.90 million | 1.88 | -$225.68 million | ($0.09) | -17.00 |
| Tempus AI | $1.27 billion | 9.18 | -$245.03 million | ($1.44) | -44.94 |
OPKO Health has higher earnings, but lower revenue than Tempus AI. Tempus AI is trading at a lower price-to-earnings ratio than OPKO Health, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares OPKO Health and Tempus AI’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| OPKO Health | -12.40% | -5.88% | -3.83% |
| Tempus AI | -17.77% | -50.28% | -10.33% |
Volatility & Risk
OPKO Health has a beta of 1.51, indicating that its stock price is 51% more volatile than the S&P 500. Comparatively, Tempus AI has a beta of 3.54, indicating that its stock price is 254% more volatile than the S&P 500.
Summary
OPKO Health beats Tempus AI on 11 of the 15 factors compared between the two stocks.
About OPKO Health
OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test. Its Pharmaceutical segment offers Rayaldee to treat secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease, and vitamin D insufficiency. This segment also develops multi-specific immune therapies focused on oncology, infectious diseases, vaccines, and immunology; OPK88004, an orally administered selective androgen receptor modulator; OPK88003, a once-weekly administered peptide for the treatment of type 2 diabetes and related obesity; Somatrogon (hGH-CTP), a once-weekly human growth hormone injection; and Factor VIIa-CTP, a novel long-acting coagulation factor being developed to treat hemophilia. In addition, it develops and commercializes longer-acting proprietary versions of already approved therapeutic proteins; develops and produces specialty APIs; develops, manufactures, markets, and sells pharmaceutical, nutraceutical, veterinary, and ophthalmic products; commercializes food supplements and over the counter products; manufactures and sells products primarily in the generics market; and markets, distributes, and sells pharmaceutical products in a range of indications, including cardiovascular products, vaccines, antibiotics, gastro-intestinal products, hormones, and others. The company also operates pharmaceutical platforms in Ireland, Chile, Spain, and Mexico. The company was founded in 1991 and is headquartered in Miami, Florida.
About Tempus AI
Tempus AI Inc. is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. Tempus AI Inc. is based in CHICAGO.
Receive News & Ratings for OPKO Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OPKO Health and related companies with MarketBeat.com's FREE daily email newsletter.
